drugset
drugset / Trial / NCT00127829

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

NCT00127829 ↗

Phase 1 Completed 66 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.

Timeline

Start
2005-07
Primary completion
—
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule — Oral

Indications

neoplasm